View all cases
UPC APP 9038/2025
Feb 28, 2025·EP2501384 · METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
- Case details
- StatusCase Closed (Claim dismissed)ActionGenericCategoryGeneric
- Parties
- Claimants
- Zentiva, k.s.Operating co.
- ZENTIVA PORTUGAL, LDAOperating co.
Representatives- Marc Lauzeral-Schertenleib
Respondents- Accord Healthcare B.V.Operating co.
- Accord Healthcare S.L.U.Operating co.
- ACCORD HEALTHCARE LIMITEDOperating co.
- Novartis AGOperating co.
Representatives- Wim Maas-Taylor Wessing
- Gregory Bacon-Bristows
- Rutger Kleemans-Freshfields
- Daniela Ampollin-Trevisan & Cuonzo
- Allard van Duijn-Freshfields
- Brian Cordery-Bristows
- Nina Bayerl-Freshfields
- Division
- Milan CD
- Technology
- ChemistryOrganic fine chemistry · Pharmaceuticals
- Language
- English
- First decided
- Mar 21, 2025
- EPO Opposition
- Fresenius Kabi Deutschland GmbHAdmissible2016-11-14
- Hamm&Wittkopp Patentanwälte PartmbBAdmissible2016-11-17
- Teva Pharmaceutical Industries LtdAdmissible2016-11-17
- Intas Pharmaceuticals Ltd.Admissible2016-11-17
- Generics (U.K.) LimitedAdmissible2016-11-17
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.Admissible2016-11-17
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Milan CD | Locked |
| Judge Andrea Postiglione | Locked |
| Judge Marije Knijff | Locked |
| Judge Oliver Werner | Locked |
At the UPC: Zentiva Group (15 cases)·Accord Group (8 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 1 other proceedings
Decisions
- 2025-03-21Application RoP313Public
Summary: The Milan Central Division dismissed Zentiva K.S. and Zentiva Portugal's application to intervene under Rule 313 RoP in infringement proceedings between Accord Healthcare and Novartis concerning EP 2 501 384. The court held that parallelism between cases or the potential impact of one judgment on another does not establish the legal interest required for intervention, and that the intervening party's requested remedies must be non-contradictory to those of the supported party.
Show the legal issues (4)
- Third party intervention under Rule 313 RoP
- Legal interest in intervention
- Res judicata and inter partes effects of UPC judgments
- Art. 33 UPCA case connections and bifurcation
Documents
| Document title | Date | Public |
|---|---|---|
| Headnote-and-Keywords | 2025-03-27 | Not public |
| Outcome of the Order | 2025-03-27 | Not public |
| ORDER 27 MARCH 2025 | 2025-03-27 | Public |
| Written submission on request to intervene by Zentiva | 2025-03-17 | Not public |
| PRELIMINARY ORDER 1st MARCH | 2025-03-01 | Not public |
| Template-Order | 2025-03-01 | Not public |
| Exhibit007 Marketing Authorization Estonian 200 mg | 2025-02-28 | Not public |
| Exhibit029 Swarco v Strabag UPC Court of First Instance Vienna Judgment of 30 July 2024 Case No UPC CFI 33 2024 | 2025-02-28 | Not public |
| Exhibit008 Marketing Authorization Portugese 200 mg | 2025-02-28 | Not public |
| Exhibit001 EP 2 501 384 B2 | 2025-02-28 | Not public |
| Exhibit013 Marketing Authorization Romania 150 mg | 2025-02-28 | Not public |
| Exhibit019 Summary of product characteristics nilotinib Zentiva BG | 2025-02-28 | Not public |
| Exhibit042 Akzo Nobel Chemicals and Akcros Chemicals v Commission CJEU 14 September 2010 Case C 550 07 P | 2025-02-28 | Not public |
| Exhibit004 Marketing Authorization Latvia 150 mg | 2025-02-28 | Not public |
| Exhibit024 Summary of product characteristics nilotinib Zentiva RO | 2025-02-28 | Not public |
| Exhibit031 NEC v TCL UPC Court of First Instance Munich Order of 2 October 2024 Case No UPC CFI 487 2023 | 2025-02-28 | Not public |
| Exhibit022 Summary of product characteristics nilotinib Zentiva LV | 2025-02-28 | Not public |
| Exhibit021 Summary of product characteristics nilotinib Zentiva LT | 2025-02-28 | Not public |
| Exhibit008 Marketing Authorization Portugese 200 mg | 2025-02-28 | Not public |
| Exhibit038 Director of the Spanish Agency of Medicines and Medical Devices n d Resolution on the termination of the mark | 2025-02-28 | Not public |
| Exhibit046 Zentiva Portugal Certificate of incorporation | 2025-02-28 | Not public |
| Exhibit024 Summary of product characteristics nilotinib Zentiva RO | 2025-02-28 | Not public |
| Exhibit027 Ocado v Autostore UPC Court of Appeal Order of 10 January 2024 Case No UPC CoA 404 2023 | 2025-02-28 | Not public |
| Exhibit044 Novartis AG v Stada PI LG Munchen I Judgment of 4 December 2024 Case No 21 O 14559 24 | 2025-02-28 | Not public |
| Exhibit041 Artegodan GmbH v European Commission CJEU Third Chamber 19 April 2012 Case C 221 10 P | 2025-02-28 | Not public |
| Exhibit014 Marketing Authorization Romania 200 mg | 2025-02-28 | Not public |
| Exhibit011 Marketing Authorization Bulgaria 200 mg | 2025-02-28 | Not public |
| Exhibit030 Seoul Viosys v Expert e Commerce UPC Court of First Instance Dusseldorf Judgment of 22 April 2024 Case No UPC | 2025-02-28 | Not public |
| Exhibit037 CE Decision revoking Decision C 2022 3252 | 2025-02-28 | Not public |
| Exhibit030 Seoul Viosys v Expert e Commerce UPC Court of First Instance Dusseldorf Judgment of 22 April 2024 Case No UPC | 2025-02-28 | Not public |
| Exhibit029 Swarco v Strabag UPC Court of First Instance Vienna Judgment of 30 July 2024 Case No UPC CFI 33 2024 | 2025-02-28 | Not public |
| Exhibit038 Director of the Spanish Agency of Medicines and Medical Devices n d Resolution on the termination of the mark | 2025-02-28 | Not public |
| Exhibit045 Zentiva k s Certificate of incorporation | 2025-02-28 | Not public |
| Exhibit026 Directive 2001 83 EC | 2025-02-28 | Not public |
| Exhibit010 Marketing Authorization Portugese 50 mg | 2025-02-28 | Not public |
| Exhibit046 Zentiva Portugal Certificate of incorporation | 2025-02-28 | Not public |
| Exhibit009 Marketing Authorization Portugese 150 mg | 2025-02-28 | Not public |
| Exhibit022 Summary of product characteristics nilotinib Zentiva LV | 2025-02-28 | Not public |
| Exhibit019 Summary of product characteristics nilotinib Zentiva BG | 2025-02-28 | Not public |
| Exhibit020 Summary of product characteristics nilotinib Zentiva EE | 2025-02-28 | Not public |
| Exhibit036 Commission v Pharmaceutical Works Polpharma S A et al CJEU 16 March 2023 joined cases C 438 21 P to C 440 21 | 2025-02-28 | Not public |
| Exhibit018 Action brought on 21 October 2024 Novartis Europharm v Commission Case T 547 24 C 2025 396 | 2025-02-28 | Not public |
| Exhibit005 Marketing Authorization Latvia 200 mg | 2025-02-28 | Not public |
| Exhibit023 Summary of product characteristics nilotinib Zentiva PT | 2025-02-28 | Not public |
| Exhibit017 Novartis second offer for a non exclusive licensee from 20240724 | 2025-02-28 | Not public |
| Exhibit016 Novartis first for a non exclusive licensee from 20210706 | 2025-02-28 | Not public |
| Exhibit023 Summary of product characteristics nilotinib Zentiva PT | 2025-02-28 | Not public |
| Exhibit034 Novartis AG v Aliud Pharma LG Munchen I Judgment of 4 December 2024 Case No 21 O 14559 24 | 2025-02-28 | Not public |
| Exhibit006 Marketing Authorization Estonian 150 mg | 2025-02-28 | Not public |
| Exhibit013 Marketing Authorization Romania 150 mg | 2025-02-28 | Not public |
| Exhibit033 MediaTek v Daedalus Prime LLC UPC Court of Appeal Order of 8 January 2025 Case No UPC CoA 621 2024 | 2025-02-28 | Not public |
| Exhibit009 Marketing Authorization Portugese 150 mg | 2025-02-28 | Not public |
| Exhibit012 Marketing Authorization Bulgaria 150 mg | 2025-02-28 | Not public |
| Exhibit010 Marketing Authorization Portugese 50 mg | 2025-02-28 | Not public |
| Exhibit025 Regulation EC No 726 2004 | 2025-02-28 | Not public |
| Exhibit039 Director of the Spanish Agency of Medicines and Medical Devices n d Resolution on the termination of the mar | 2025-02-28 | Not public |
| Exhibit020 Summary of product characteristics nilotinib Zentiva EE | 2025-02-28 | Not public |
| Exhibit044 Novartis AG v Stada PI LG Munchen I Judgment of 4 December 2024 Case No 21 O 14559 24 | 2025-02-28 | Not public |
| Exhibit040 European Ferries and Diputacion Foral de Vizcaya v Commission CJEU 1 June 2006 joined Cases C 442 03 P and C | 2025-02-28 | Not public |
| Exhibit028 Insulet Menarini UPC Court of First Instance Milan Procedural Order of 23 December 2024 Case No UPC CFI 380 2 | 2025-02-28 | Not public |
| Exhibit007 Marketing Authorization Estonian 200 mg | 2025-02-28 | Not public |
| Exhibit011 Marketing Authorization Bulgaria 200 mg | 2025-02-28 | Not public |
| Application | 2025-02-28 | Not public |
| Exhibit006 Marketing Authorization Estonian 150 mg | 2025-02-28 | Not public |
| Exhibit034 Novartis AG v Aliud Pharma LG Munchen I Judgment of 4 December 2024 Case No 21 O 14559 24 | 2025-02-28 | Not public |
| Exhibit021 Summary of product characteristics nilotinib Zentiva LT | 2025-02-28 | Not public |
| Exhibit043 Insulet v Menarini UPC Court of First Instance Milan Procedural Order of 1 October 2024 Case No UPC CFI 380 2 | 2025-02-28 | Not public |
| Exhibit012 Marketing Authorization Bulgaria 150 mg | 2025-02-28 | Not public |
| Exhibit032 Dolby v HP Deutschland UPC Court of First Instance Dusseldorf Judgment of 26 June 2024 Case No UPC CFI 457 20 | 2025-02-28 | Not public |
| Exhibit015 Marketing Authorization Lituania 150 mg and 200 mg | 2025-02-28 | Not public |
| Exhibit032 Dolby v HP Deutschland UPC Court of First Instance Dusseldorf Judgment of 26 June 2024 Case No UPC CFI 457 20 | 2025-02-28 | Not public |
| Exhibit035 STADAPHARM v Novartis and Accord Healthcare UPC Court of First Instance Milan Preliminary Order of 3 February | 2025-02-28 | Not public |
| Exhibit002 SmPC Tasigna Novartis | 2025-02-28 | Not public |
| Exhibit039 Director of the Spanish Agency of Medicines and Medical Devices n d Resolution on the termination of the mar | 2025-02-28 | Not public |
| Exhibit045 Zentiva k s Certificate of incorporation | 2025-02-28 | Not public |
| Exhibit003 SmPC nilotinib Accord Healthcare | 2025-02-28 | Not public |
| Exhibit014 Marketing Authorization Romania 200 mg | 2025-02-28 | Not public |